skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
CDK2/TRKA Inhibitor PHA-848125 AC (Code C88312)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: CDK2/TRKA Inhibitor PHA-848125 AC

Definition: An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.

Label: CDK2/TRKA Inhibitor PHA-848125 AC

NCI Thesaurus Code: C88312 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2934615  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CDK2/TRKA Inhibitor PHA-848125 AC
PHA-848125 AC

External Source Codes: 
PDQ Closed Trial Search ID 660138
PDQ Open Trial Search ID 660138 (check for NCI PDQ open clinical trial info)
UMLS CUI C2934615

Other Properties:
     Name Value (qualifiers indented underneath)
code C88312
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom